KALA BIO, Inc. (KALA)
$0.69-$0.12 (-15.01%) Today
Todd BazemoreKala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
No Form 4 activity for KALA in the last 90 days.
14 Form 4 filings on record, the earliest from Dec 31, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David E. Lazar - Officer | Grant or award | Series AA Convertible Preferred Stock | 900,000 | - | - | |
| Darius Kharabi - Officer | Open-market sale | Common Stock | 20,806 | $41.50 | $17K | |
| Mark T. Iwicki | Open-market sale | Common Stock | 154,894 | $40.50 | $125K | |
| Todd Bazemore | Open-market sale | Common Stock | 47,768 | $41.50 | $40K | |
| Romulus K. Brazzell - Officer | Open-market sale | Common Stock | 46,748 | $41.50 | $39K | |
| Mary Reumuth - Officer | Open-market sale | Common Stock | 32,230 | $41.50 | $27K | |
| Mary Reumuth - Officer | Open-market sale | Common Stock | 967 | $41.00 | $793 | |
| BAKER BROS. ADVISORS LP | Open-market sale | Common Stock | 21,376 | $79.80 | $34K | |
| BAKER BROS. ADVISORS LP | Open-market sale | Common Stock | 195,425 | $79.80 | $312K | |
| BAKER BROS. ADVISORS LP | Open-market sale | Common Stock | 50,640 | $69.19 | $70K | |
| BAKER BROS. ADVISORS LP | Open-market sale | Common Stock | 462,967 | $69.19 | $641K | |
| Todd Bazemore - Officer | Grant or award | Stock Option (right to buy) | 180,000 | $0.00 | - | |
| Romulus K. Brazzell - Officer | Open-market sale | Common Stock | 5,251 | $200.50 | $21K | |
 Andrew I. Koven | Grant or award | Common Stock | 3,050 | $0.00 | - | |
| Andrew I. Koven | Grant or award | Stock Option (right to buy) | 6,850 | $0.00 | - | |
| Gregory D. Perry | Grant or award | Common Stock | 2,450 | $0.00 | - | |
| Gregory D. Perry | Grant or award | Stock Option (right to buy) | 5,450 | $0.00 | - | |
| Howard B. Rosen | Grant or award | Common Stock | 2,450 | $0.00 | - | |
| Howard B. Rosen | Grant or award | Stock Option (right to buy) | 5,450 | $0.00 | - | |
| Romulus K. Brazzell - Officer | Open-market sale | Common Stock | 3,687 | $187.00 | $14K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 30,620 | $322.00 | $197K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 279,939 | $322.00 | $1.80M |
KALA BIO, Inc. (KALA) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-11-26. The full record for KALA runs to 14 Form 4 filings, the earliest from 2024-12-31. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of KALA were filed in the last 90 days. 2 purchases are on record for this company.
No insider sales of KALA were filed in the last 90 days. 12 sales are on record for this company.
This page tracks KALA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add KALA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$KALVKalVista Pharmaceuticals, Inc.
$KANTKINETA, INC./DE
$KIDSORTHOPEDIATRICS CORP
$KLCKinderCare Learning Companies, Inc.
$KLRSKalaris Therapeutics, Inc.
$KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.
$KNSAKiniksa Pharmaceuticals International, plc
$KODKodiak Sciences Inc.
$KPRXKIORA PHARMACEUTICALS INC
$KPTIKaryopharm Therapeutics Inc.Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
